Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara (SVRA – Research Report) and Zentalis Pharmaceuticals ...

(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low, touching down at $1.76, as the biopharmaceutical company grapples with a challenging market environment. According to InvestingPro ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"Zentalis reported significant progress in the ... Continuing patient enrollment across clinical pipeline. The Company is continuing to enroll patients in its ZN-c3-002 Phase 1b dose escalation ...

"Zentalis reported significant progress in the development ... Together with the other members of the leadership team, the Company refined and sharpened its pipeline. In January 2025, the Company ...

"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...